


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-13.89%
-0.58%
-3.05%
-1.97%
DHR
Danaher
$205.23
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
DHR Price Performance
$234.33 (-12.42%)
$222.41 (-7.72%)
$189.72 (+8.18%)
$205.88 (-0.32%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
DHR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
DHR Street Sentiment is extremely bullish and have positive views on the near-term outlook
DHR has Low risk level

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Dec 09, 2025
Initiate
Buy
Goldman Sachs
Dec 03, 2025
Initiate
Overweight
Morgan Stanley
Oct 23, 2025
Reiterate
Buy
TD Cowen
Oct 22, 2025
Reiterate
Overweight
Barclays
Oct 08, 2025
Reiterate
Outperform
Evercore ISI
What is DHR current stock price?
What are DHR stock strengths?
What is DHR Risk Level?
What is DHR market cap and volume?
What is DHR current Stock IQ?
Should I buy DHR stock right now?
Is DHR a Strong Buy right now?
What does a 'Strong Buy' rating mean for DHR?
What does a 'Strong Sell' rating mean for DHR?
What factors influence DHR's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-13.89%
-0.58%
-3.05%
-1.97%
DHR
Danaher
Current Price
$205.23

DHR Price Performance
$234.33 (-12.42%)
$222.41 (-7.72%)
$189.72 (+8.18%)
$205.88 (-0.32%)
DHR Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
DHR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
DHR Street Sentiment is extremely bullish and have positive views on the near-term outlook
DHR has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Dec 09, 2025
Initiate
Buy
Goldman Sachs
Dec 03, 2025
Initiate
Overweight
Morgan Stanley
Oct 23, 2025
Reiterate
Buy
TD Cowen
Oct 22, 2025
Reiterate
Overweight
Barclays
Oct 08, 2025
Reiterate
Outperform
Evercore ISI
DHR Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
DHR Latest Analysis
Danaher to Buy Medical Tech Firm Masimo for $9.9 Billion. Danaher Corp. agreed to buy Masimo Corp. in a deal with an enterprise value of about $9.9 billion allowing it to gain a foothold in the medical supply business.
Today
Danaher Corp. (DHR) Signaled Signs of a Stable Bioprocessing Segment. Meridian Funds managed by ArrowMark Partners released its fourth-quarter 2025 investor letter for Meridian Hedged Equity Fund. A copy of the letter can be downloaded here. United States equity markets experienced a quarter supported by optimism about potential monetary easing and caution regarding economic growth and valuations. Early gains were driven by strong AI-related earnings and [….]
Today
Danaher Agrees to Buy Medical Tech Firm Masimo for $9.9 Billion. Danaher Corp. agreed to buy US medical technology firm Masimo Corp. in a deal with an enterprise value of about $9.9 billion.
Today
Danaher Said to Near $10 Billion Deal for Masimo FT Reports. Danaher Corp. is nearing a roughly $10 billion deal to acquire US medical technology firm Masimo Corp. the Financial Times reported citing unidentified people familiar with the matter.
Today
Danaher Stock Plunge Does Not Represent A Good Entry Point.
Fri Jan 30, 2026
Danaher Corporation (NYSE:DHR) Q4 2025 Earnings Call Transcript. Danaher Corporation (NYSE:DHR) Q4 2025 Earnings Call Transcript January 28 2026 Danaher Corporation beats earnings expectations. Reported EPS is $2.23 expectations were $2.16. Operator: To all sites on hold we would like to thank you for your patience. Please continue to stand by. Your personal begin here shortly. Please standby. Good day everyone. My name [….]
Thu Jan 29, 2026
Danaher Q4 Earnings Beat Estimates Life Sciences Sales Up Y/Y. DHR beats Q4 estimates as sales rise 4.5% driven by strength across Life Sciences Diagnostics and Biotech and issued upbeat 2026 earnings guidance.
Wed Jan 28, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.